Check out our psoriatic arthritis coverage from #EULAR2021. Head to RheumNow for full EULAR coverage. https://t.co/NzB2e2Vfwb

• https://bit.ly/3vQajub

RheumNow’s expanded coverage of the #EULAR2021 meeting is sponsored in part by Novartis, Bristol Myers Squibb, Janssen. All content chosen by RheumNow & its Faculty.

What about musculoskeletal #pain in PsO patients? Results of a nationwide Danish survey #POS0149 that shed light into unadressed reduced quality of life and risk to move towards #PsA #EULAR2021 @RheumNow https://t.co/JQnHSvtpHm

Data from the COSMOS study showed that 44.4% of patients who received #guselkumab versus 19.8% of patients who received placebo achieved a ≥20% improvement at week 24. #psoriaticarthritis https://t.co/S3xnFSQDaJ

• Improved Psoriatic Arthritis Outcomes in Phase 3b Guselkinumab Trial

PROs in Spa and PSA: Dr. Rachel Tate ( @uptoTate) https://t.co/sUXTXDXrFh

• PROs in Spa and PSA: Dr. Rachel Tate | RheumNow

An original way of differentiating RA from PsA! The shape of the second MCP in HR-pQCT is enough to train a neural network with high accuracy for recognition of -HC 94% -RA 84% -PsA 89% and an AUC of 91%. #EULAR2021 @RheumNow #OP0145 https://t.co/BrwFQpX310

Q-DAPSA (DAPSA + CRP), validated as a clinical measure of PsA disease activity in both practice & research from 5 centers in Berlin, 104 PsA pts. Let's get more studies to better understand the power of this measure. Poster #POS1069 #EULAR2021 @RheumNow https://t.co/X4UWGwH5i5 https://t.co/J7EpOjTjhe

• https://ard.bmj.com/content/80/Suppl_1/813

SPACING trial: possible to taper TNFi in AxSpA pts in LDA ⭐️Tapering of TNFi in axSpA resulted in 88% BASDAI<4 compared to 91.5% in unchanged group ⭐️adalimumab spaced out to q35 days Abs#OP0138 #EULAR2021 @RheumNow